Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [6]. Core Insights - The company is expected to experience a revenue growth of 1.1% year-on-year in 2025, primarily impacted by a slowdown in domestic milk powder business [1]. - The forecasted net profit for 2025 is expected to remain flat compared to the previous year, with a decline in profit anticipated in the second half of 2025 due to slower internal code adjustments and increased industry competition [1][2]. - The company is projected to see a moderate improvement in revenue growth in 2026, supported by the completion of internal code switching and a low base effect from 2025 [3]. Revenue and Profit Forecast - The company's revenue for 2025 is estimated at 7.487 billion yuan, with a slight increase from 2024 [5]. - The net profit for 2025 is projected to be 236 million yuan, remaining stable compared to 2024 [5]. - Earnings per share (EPS) for 2025 is expected to be 0.13 yuan, with a price-to-earnings (P/E) ratio of 13x [4][5]. Market and Competitive Environment - The internal code switching process has been delayed, affecting the company's growth momentum in the second half of 2025 [2]. - Increased competition in the industry has led to other companies offering subsidies or price reductions, putting the company in a disadvantageous position during its price increase phase [2]. - The company’s overseas business is expected to be a significant growth driver, particularly in markets like the Middle East and Southeast Asia, with plans to launch products in India by 2027 [3]. Valuation Metrics - The report adjusts the net profit forecasts for 2025-2027 to 236 million, 262 million, and 280 million yuan respectively, reflecting a cautious outlook due to declining birth rates and intensified competition [4]. - The projected P/E ratios for 2025, 2026, and 2027 are 13x, 12x, and 11x respectively, indicating a relatively stable valuation in the coming years [4].
澳优（01717）：——澳优（1717.HK）2025年业绩前瞻：因内码调整进度偏慢拖累，预计25H2业绩承压